Premium
The use of micronised progesterone for menopausal hormone therapy, a clinical practice audit
Author(s) -
Davis Susan R.,
Dempster Georgia,
Bell Robin J.
Publication year - 2016
Publication title -
australian and new zealand journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.734
H-Index - 65
eISSN - 1479-828X
pISSN - 0004-8666
DOI - 10.1111/ajo.12453
Subject(s) - discontinuation , medicine , audit , hormone therapy , gynecology , clinical practice , menopause , obstetrics , physical therapy , cancer , economics , management , breast cancer
A clinical practice audit was undertaken to share an Australian experience of the use of micronised progesterone ( mP ) 100 mg daily as part of menopausal hormone therapy ( MHT ). Ninety‐nine women attending a single practitioner were offered the option of mP as a component of MHT , under the Australian Authorised Prescriber Scheme, over 2.5 years. Each of their files was independently audited. The mean age at commencement was 55.0 ( SD 6.6) years. Of the 93 postmenopausal women, 7 were lost to follow‐up, 18 discontinued and treatment was ongoing for 68. The mean duration of treatment for those ongoing was 1.7 ( SD 0.5) years, and for those who discontinued, 0.6 ( SD 0.6) years. The most common side effect was unscheduled bleeding, which was also the most common reason for discontinuation (5/18 women). None of the 15 women who had a transvaginal ultrasound examination had an endometrial thickness >5 mm. Of the 41 women who had at least one blood progesterone measurement performed, the median value was 11.3 (range 0.7–138) nmol/L. This audit indicates that mP is well tolerated when prescribed as MHT . Although there was no evidence of endometrial hyperplasia, further research is needed to establish the safety of mP for continuous combined MHT use.